Previous 10 | Next 10 |
Palm Beach, FL – June 30, 2021 – Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and much research is devoted to this market. AF is responsible for most arrhythmia-related hospitalizations and leads to the greatest length of hospital stay associated w...
Shares of Stereotaxis Inc. (NYSE American:STXS) traded at a new 52-week high today of $10.28. This new high was reached on below average trading volume as 192,000 shares traded hands, while the average 30-day volume is approximately 550,000 shares. In the past 52 weeks, Stereotaxis Inc. ...
Shares of Stereotaxis Inc. (NYSE American:STXS) traded at a new 52-week high today of $9.23. Approximately 188,000 shares have changed hands today, as compared to an average 30-day volume of 474,000 shares. In the past 52 weeks, Stereotaxis Inc. share prices are bracketed by a low of $3....
Stereotaxis Inc. (NYSE American:STXS) traded today at a new 52-week high of $9.00. This new high was reached on below average trading volume as 226,000 shares traded hands, while the average 30-day volume is approximately 434,000 shares. Stereotaxis Inc. share prices have moved between a...
Stereotaxis reported $8.6 million of sales in Q1 which beat estimates by $1.4 million. Yearly growth was 49.8%. The company sold another replacement system since the last conference call 2 months ago. There should be another system sale through this hospital network. Procedure vol...
Stereotaxis, Inc. (STXS) Q1 2021 Earnings Conference Call May 10, 2021, 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - Cowen Jason Wittes - Northland Presentation Opera...
Image source: The Motley Fool. Stereotaxis (NYSEMKT: STXS) Q1 2021 Earnings Call May 10, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Stereotaxis (STXS) Q1 2021 Earnings Call Transcript
Stereotaxis shares up ([[STXS]] +3.0%) after posting first-quarter results that beat Wall Street estimates, helped by the sales of its Genesis RMN and Niobe systems.The company's revenue in the quarter increased 50% to $8.6M, beating analysts' average estimate by $1.4M.Gross margin for t...
ST. LOUIS, May 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021. “The highlight of the first quar...
ST. LOUIS, April 19, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the ope...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...